
Moderna, Inc. has secured FDA approval for Spikevax's use in ages 12 and above, while also receiving Emergency Use Authorization for 6 months to 11 years. This updated COVID-19 vaccine targets the XBB.1.5 sublineage of SARS-CoV-2, bolstering protection for those aged 6 months and older. Moderna is now set to distribute doses to vaccination sites across the U.S., making the updated vaccine accessible in the near future.
Like
Save
Share